Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by FredTheVoiceon Mar 09, 2018 9:47am
149 Views
Post# 27690274

THE question from now on

THE question from now on
PALINC2000 wrote:  "Great label!!! GIves the user so much confidence for such amazing potential results with so few and minor adverse effects..Safe and effective.
Market penetration might surprise to the upside "

Good post. Because a lot of questions were stopped lately with all that waiting for approval. Now, we were right to be confident and we slamed a homerun. But this is the first inning,

THE QUESTION from now on is : is this drug will become (and how fast if its a YES) a commercialisation success. As PALINC is putting ahead: how fast and surprising will be the MARKET PENETRATION. Because the answer to this will effect approbation process in EUROPE and CANADA, because they will want to offer that succes if it becomes what we all think.......

SOME ANSWERS coming soon. And thats all exciting.

FTV.

 
Bullboard Posts